Claims for Patent: 10,239,846

Summary for Patent: 10,239,846

Title:	Selective sphingosine 1 phosphate receptor modulators and methods of chiral synthesis
Abstract:	Compounds that selectively modulate the sphingosine 1 phosphate receptor are provided including compounds which modulate subtype 1 of the S1P receptor. Methods of chiral synthesis of such compounds are provided. Uses, methods of treatment or prevention and methods of preparing inventive compositions including inventive compounds are provided in connection with the treatment or prevention of diseases, malconditions, and disorders for which modulation of the sphingosine 1 phosphate receptor is medically indicated.
Inventor(s):	Martinborough; Esther (San Diego, CA), Boehm; Marcus F. (San Diego, CA), Yeager; Adam Richard (La Mesa, CA), Tamiya; Junko (Carlsbad, CA), Huang; Liming (San Diego, CA), Brahmachary; Enugurthi (San Diego, CA), Moorjani; Manisha (San Diego, CA), Timony; Gregg Alan (San Diego, CA), Brooks; Jennifer L. (Encinitas, CA), Peach; Robert (San Diego, CA), Scott; Fiona Lorraine (San Diego, CA), Hanson; Michael Allen (San Marcos, CA)
Assignee:	CELGENE INTERNATIONAL II S RL (Couvet, CH)
Application Number:	15/406,128
Patent Claims:	1. A method for treating ulcerative colitis comprising administering an effective amount of a compound having the structure of Formula I-R or I-S or a pharmaceutically acceptable salt thereof to a patient at a frequency and for a duration of time sufficient to provide a beneficial effect to the patient: ##STR00403## wherein X is --NHCH.sub.2CH.sub.2OH; and Y is --CN. 2. The method of claim 1 wherein the compound has the structure of Formula I-R or a pharmaceutically acceptable salt thereof. 3. The method of claim 2 wherein the pharmaceutically acceptable salt is a hydrochloric acid (HCl) salt. 4. The method of claim 1 wherein the compound has the structure of Formula I-S or a pharmaceutically acceptable salt thereof. 5. The method of claim 4 wherein the pharmaceutically acceptable salt is a hydrochloric acid (HCl) salt. 6. A method for treating Crohn's disease comprising administering an effective amount of a compound having the structure of Formula I-R or I-S or a pharmaceutically acceptable salt thereof to a patient at a frequency and for a duration of time sufficient to provide a beneficial effect to the patient: ##STR00404## wherein X is --NHCH.sub.2CH.sub.2OH; and Y is --CN. 7. The method of claim 6 wherein the compound has the structure of Formula I-R or a pharmaceutically acceptable salt thereof. 8. The method of claim 7 wherein the pharmaceutically acceptable salt is a hydrochloric acid (HCl) salt. 9. The method of claim 6 wherein the compound has the structure of Formula I-S or a pharmaceutically acceptable salt thereof. 10. The method of claim 9 wherein the pharmaceutically acceptable salt a hydrochloric acid (HCl) salt.